EDUCATIONAL COMMENTARY NEUROLOGIC AUTOIMMUNE DISEASES
|
|
- Edwin Oliver
- 5 years ago
- Views:
Transcription
1 EDUCATIONAL COMMENTARY NEUROLOGIC AUTOIMMUNE DISEASES Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits, click on Earn CE Credits under Continuing Education on the left side of the screen. Learning Outcomes On completion of this exercise, the participant should be able to: describe neurologic diseases such as myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP); identify neurologic tests that are used to diagnose these diseases; and discuss treatment options for these diseases. Educational Commentary Neurologic autoimmune diseases are caused by antibodies against the body s own nervous system structures, most often neural receptors. Diseases such as myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) are neurologic disorders mediated by immune dysregulation. Myasthenia Gravis Myasthenia gravis affects 8 to 10 per 1 million persons annually. 1 It has a bimodal age distribution, affecting individuals in either the second to third decades or sixth to eighth decades. 2 Generalized and ocular MG are the two clinical forms of the disease. This neuromuscular transmission disorder is caused by the development of autoantibodies to neural receptors at neuromuscular junctions, such as the acetylcholine receptors (AChR), muscle-specific kinase receptors (MuSK), and the lipoprotein receptor related protein 4 (LRP4). 1-3 When bound, these antibodies cause symmetric, proximal skeletal muscle weakness, which worsens with repetitive muscular activity. The muscles that are predominantly affected are the muscles of the mouth and throat, respiratory tract, and limbs. When present, ocular weakness affects the eyes asymmetrically. 1-4 Ocular MG is present in 15% of patients diagnosed as having MG. 1,4 This symptom causes weakness and fatigability of the extraocular muscles, leading to drooping of the eyelids and double vision. Myasthenia gravis can be further subgrouped by the presence or lack of a detectable antibody (seropositivity or seronegativity, respectively); if seropositive, it is further classified by the receptor to which the antibody binds, or the presence of thymoma. 1 Prognosis and treatment of MG may vary depending on subgroup. For example, patients who are MuSK antibody positive respond to treatment with therapeutic plasma exchange (TPE) rather than intravenous immunoglobulin (IVIG).
2 Diagnosis In the natural progression of MG, symptoms are mild early in the disease, with worsening and persistence as the disease progresses. For most patients, maximal weakness develops within two to three years of disease onset. 5,6 Myasthenia gravis is diagnosed by reviewing the patient s medical history and laboratory testing and imaging results. Tests include the edrophonium test, the ice pack test, and serologic and electrophysiologic testing. Bedside testing includes edrophonium testing and the ice pack test. Edrophonium chloride is an acetylcholinesterase inhibitor that causes an increase in ocular muscle strength. 7 This test should be performed in patients with drooping eyelids or ptosis only. The test is very sensitive, meaning that there is a high chance of a false-positive result. The ice pack test is an alternate bedside test, performed by placing an ice pack on the eyelid to improve neuromuscular transmission, thus strengthening the eyelid. 8 Serologic testing for autoantibodies is the laboratory confirmation of the disease. Blood for this test should be drawn before initiating immunotherapy. AChR antibodies are found in approximately 98% of patients with MG and thymoma. 9 However, antibody titers do not correlate well with disease severity. MuSK antibodies are found in approximately 40% of patients who are seronegative for AChR antibodies. 10 Persons who are MuSK positive usually do not have associated thymic disease. Seronegativity is also seen in patients with MG, as there are potentially many antibodies mediating MG that have not yet been identified. Electrophysiologic testing includes repetitive nerve stimulation and single-fiber electromyography. Repetitive nerve stimulation is performed by stimulating the motor nerve to a particular muscle. The nerve stimulation is recorded by an electrode placed over the endplate regions of the muscle. A decrement in nerve response indicates disorders of neuromuscular transmission, including MG. Singlefiber electromyography is a more sensitive test for MG than repetitive nerve stimulation. This test is more technically challenging, as it records the neuromuscular transmission of several muscle fibers by one motor axon. 11 Mediastinal imaging can be used to detect a thymoma, which can affect the patient s prognosis. Treatment There are multiple treatment options for MG, including cholinesterase inhibitors, thymectomy, immunosuppression, TPE, and IVIG. 12 Cholinesterase inhibitors are effective in MG and work by increasing the release of acetylcholine in the presynaptic cleft. 1 Patients who are MuSK positive do not respond as well to this treatment as persons with the other subgroups of MG. This is an effective sole treatment for those with mild disease.
3 Immunosuppressive treatments such as prednisone, azathioprine, mycophenolate mofetil, and rituximab are also options in patients whose symptoms are not adequately controlled by cholinesterase inhibitors. 1 These medications have different mechanisms of action to decrease the persistent MG symptoms of weakness and fatigue. They can produce adverse effects, such as abdominal cramping, decreased heart rate, and sweating, and it may take months before a therapeutic benefit is seen. Removal of the thymus gland, thymectomy, leads to delayed improvement with some patients experiencing improvements years postthymectomy. 12 Therapeutic plasma exchange is used to decrease the titers of the autoantibodies by removing the patient s plasma and exchanging it with a replacement fluid such as albumin. 13 According to the American Society for Apheresis guidelines, TPE is a category I treatment for moderate to severe MG and individuals with MG before thymectomy. 12 The term category I treatment for a disease or indication means that it can be used as a first-line treatment for that disease. The treatment protocol is a 1.0 plasma volume exchange daily or every other day for 2 weeks followed by a taper. 12 Although the therapeutic benefit of TPE may be seen early, the effect is not sustained long-term unless immunosuppressive therapies are part of the treatment regimen. Intravenous immunoglobulin treatment uses pooled donor immunoglobulin. 14 The mechanism of action is unknown but symptomatic improvement can be seen early, with improvement lasting 3 to 6 weeks. A comparison of TPE and IVIG showed that TPE was potentially more effective than IVIG in patients with impending respiratory failure. 12 Chronic Inflammatory Demyelinating Polyneuropathy Chronic inflammatory demyelinating polyneuropathy is an autoimmune disease that affects the peripheral nerves and nerve roots. 15,16 Similar to MG, it is a common autoimmune neuropathy. The cause of CIDP remains uncertain but the disease is believed to be mediated by both antibody and T-cell immune responses. The target antigens of the antibodies are currently unknown. Studies have postulated several antibodies to myelin components including β-tubulin and GM1. 17 There is also an increase in inflammatory cytokines such as tumor necrosis factor and interleukins. This disease, which is believed to be underdiagnosed, affects 1 to 2 per 100,000 adults. 16 It affects individuals in the third and sixth decades. 16,18 CIDP is heterogenous and has many subgroups including Lewis-Sumner syndrome, sensory-predominant CIDP and CIDP with central nervous system involvement. The classic form of the disease causes symmetric proximal and distal muscle weakness, peripheral nerve tingling, depressed reflexes, and balance problems. 17 The disease progressively worsens within 2 months of onset. 16
4 Diagnosis Chronic inflammatory demyelinating polyneuropathy is diagnosed by reviewing the patient s medical history, laboratory testing, and muscle biopsy showing peripheral nerve demyelination. Because of the complexity in diagnosing CIDP, many diagnostic criteria have been published to aid the physician, including the Koski classification and the European Federation of Neurological Societies / Peripheral Nerve Society (EFNS/PNS) Guideline Electrodiagnostic testing shows slow conduction velocity, conduction blocks, and reduced evoked potential amplitude. 18 Cerebrospinal fluid analysis shows dramatically elevated protein levels (6-fold increase) with a normal white blood cell count. 15,16 Muscle biopsy shows demyelination and remyelination of the peripheral nerves. 16 Cerebrospinal fluid testing and muscle biopsy are not required for diagnosing CIDP but are helpful in patients with inconclusive electrodiagnostic results. Treatment Treatment for CIDP includes corticosteroids, immunosuppressive therapies, TPE, and IVIG to help increase strength, motor performance, and balance. Patients with CIDP are first treated with high-dose steroids ( mg/d) for at least 1 month. 16,18 The medication is slowly tapered. There are long-term adverse effects, including triggering of diabetes, osteoporosis, and the formation of cataracts. Immunosuppressive drugs such as cyclosporine, azathioprine, and methotrexate can be used as secondary treatment in patients with progressive CIDP symptoms. 12 Therapeutic plasma exchange and IVIG are equivalent treatments based on clinical trials that compared their efficacy. 23 Therapeutic plasma exchange is a category I treatment for CIDP, used as a first-line treatment for this disease. 12 In clinical trials, patients with CIDP who were treated with TPE had better motor function, motor amplitude, and nerve conduction. 12,17 Patients with CIDP who are not ambulatory cannot be tapered from corticosteroids, and nonresponders to IVIG should receive TPE as part of their treatment plan. The treatment plan varies but a suggested plan is two to three TPE treatments per week until the patient improves, followed by a taper. 12 Conclusion Neurological disorders such as MG and CIDP are autoimmune disorders affecting nervous system structures. These disorders can be appropriately diagnosed using various neurologic and laboratory testing methods and can be treated with medications and therapies such as therapeutic plasma exchange.
5 References 1. Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26): Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol. 2016;263(4): Aarli JA, Gilhus NE, Lisak RP, Mantegazza R, Suzuki S. Myasthenia gravis. Autoimmune Dis. 2011;2011: Smith SV, Lee AG. Update on ocular myasthenia gravis. Neurol Clin. 2017;35(1): Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2): Mantegazza R, Beghi E, Pareyson D, et al. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol. 1990;237(6): Pascuzzi RM. The edrophonium test. Semin Neurol. 2003;23(1): Golnik KC, Pena R, Lee AG, Eggenberger ER. An ice test for the diagnosis of myasthenia gravis. Ophthalmology. 1999;106(7): Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res. 2004;10(21): McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55(4): Stålberg E, Trontelj JV. Single Fibre Electromyography. Old Working, Surrey, UK: The Miravalle Press Limited; Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31(3): Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002(4):CD Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23): Latov N, Dalakas M, Vallat JM, Donofrio P, Hartung HP, Toyka KV. Biomarkers in the diagnosis and therapy of CIDP: Proceedings of the Biomarkers Faculty Meeting; June 8-9, 2010, Athens, Greece. J Peripher Nerv Syst. 2011;16(suppl 1): Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352(13): McLeod BC. Therapeutic apheresis in neurologic disorders. In: McLeod BC, Szczepiorkowski ZM, Weinstein R, Winters JL, eds. Apheresis: Principles and Practice. 3rd ed. Bethesda, Maryland: AABB; 2010.
6 18. Dalakas MC, Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011;7(9): Nicolas G, Maisonobe T, Le Forestier N, Leger JM, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2002;25(1): Van den Bergh PY, Pieret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004;29(4): Koski CL, Baumgarten M, Magder LS, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2009;277(1-2): Van den Bergh PY, Hadden RD, Bouche P, et al; European Federation of Neurological Societies/ Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010;17(3): Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36(6): ASCP
Myasthenia Gravis. Mike Gilchrist 10/30/06
Myasthenia Gravis Mike Gilchrist 10/30/06 Overview Background Pathogenesis Clinical Manifestations Diagnosis Treatment Associated Conditions Background Severe muscle disease Most common disorder of neuromuscular
More informationPeripheral neuropathies, neuromuscular junction disorders, & CNS myelin diseases
Peripheral neuropathies, neuromuscular junction disorders, & CNS myelin diseases Peripheral neuropathies according to which part affected Axonal Demyelinating with axonal sparing Many times: mixed features
More informationCLINICAL PRESENTATION
MYASTHENIA GRAVIS INTRODUCTION Most common primary disorder of neuromuscular transmission Usually due to acquired immunological abnormality Also due to genetic abnormalities at neuromuscular junction.
More information8/13/2018. Update in Myasthenia Gravis. Ikjae Lee, MD. None
Update in Myasthenia Gravis Ikjae Lee, MD Assistant professor, UAB Neuromuscular Medicine 2018 Alabama Academy of Neurology Annual Meeting Disclosure None Page 2 Contents Overview of Myasthenia Gravis
More informationComparison of IVIg and PLEX in patients with myasthenia gravis
Comparison of IVIg and PLEX in patients with myasthenia gravis D. Barth, MD M. Nabavi Nouri, MD E. Ng, MD P. Nwe, MD V. Bril, MD Address correspondence and reprint requests to Dr. Vera Bril, 5EC-309, Toronto
More informationComparison of diabetes patients with demyelinating diabetic sensorimotor polyneuropathy to those diagnosed with CIDP
Comparison of diabetes patients with demyelinating diabetic sensorimotor polyneuropathy to those diagnosed with CIDP Samantha K. Dunnigan 1, Hamid Ebadi 1, Ari Breiner 1, Hans D. Katzberg 1, Leif E. Lovblom
More informationMyasthenia gravis. David Hilton-Jones Oxford Neuromuscular Centre
Myasthenia gravis David Hilton-Jones Oxford Neuromuscular Centre SWIM, Taunton, 2018 Myasthenia gravis Autoimmune disease Nature of Role of thymus Myasthenia gravis Autoimmune disease Nature of Role of
More informationAnswers to Self Assessment Questions
Answers to Self Assessment Questions 1. Which of the following findings is supportive of the diagnosis of multifocal motor neuropathy (MMN): A. Absence of conduction block (CB) on nerve conduction studies
More informationDiagnosis and Management of Immune-mediated Neuropathies
Continuing Medical Education 39 Diagnosis and Management of Immune-mediated Neuropathies Sung-Tsang Hsieh Abstract- Immune-mediate neuropathies, or inflammatory neuropathies are neuropathies due to the
More informationMyasthenia: Is Medical Therapy in the Grave? Katy Marino, PGY-5
Myasthenia: Is Medical Therapy in the Grave? Katy Marino, PGY-5 Disclosures Outline History of Thymus Anatomy of Thymus Pathophysiology of Myasthenia Gravis Medical Management of Myasthenia Gravis Surgical
More informationThe clinical spectrum of Malaysian patients with. Chronic inflammatory demyelinating polyneuropathy
Neurology Asia 2004; 9 : 39 45 The clinical spectrum of Malaysian patients with chronic inflammatory demyelinating polyneuropathy Khean Jin GOH, Wai Keong NG, Nee Kong CHEW, Chong Tin TAN Division of Neurology,
More informationSevere Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy
doi: 10.2169/internalmedicine.1723-18 http://internmed.jp CASE REPORT Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy
More informationMyasthenia gravis (MG) is an autoimmune disorder
Brief Communication The clinical features of patients concurrent with Guillain-Barré syndrome and myasthenia gravis Junliang Yuan, MD, Juan Zhang, MD, ABSTRACT Bingwei Zhang, MD, Wenli Hu, MD. Objectives:
More informationMyasthenia gravis. Page 1 of 7
Myasthenia gravis What is myasthenia gravis? Myasthenia gravis (sometimes abbreviated to MG) is a chronic, autoimmune condition that causes muscle weakness and excessive muscle fatigue. It is rare, affecting
More informationRandomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine - August 11, 2016
Randomized Trial of Thymectomy in Myasthenia Gravis New England Journal of Medicine - August 11, 2016 Disclosures None At all. Example Case 38 year-old female with no pertinent PMH who presents with a
More informationMyasthenia Gravis What is Myasthenia Gravis? Who is at risk of developing MG? Is MG hereditary? What are the symptoms of MG? What causes MG?
Myasthenia Gravis What is Myasthenia Gravis? Myasthenia Gravis (MG) is a chronic, autoimmune disease that causes muscle weakness and excessive muscle fatigue. It is uncommon, affecting about 15 in every
More informationINTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES
International Journal of Institutional Pharmacy and Life Sciences 5(5): September-October 2015 INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES Pharmaceutical Sciences Review Article!!!
More informationStanley Iyadurai, PhD MD. Assistant Professor of Neurology/Neuromuscular Medicine Nationwide Children s Hospital Myology Course 2015
1 Stanley Iyadurai, PhD MD Assistant Professor of Neurology/Neuromuscular Medicine Nationwide Children s Hospital Myology Course 2015 Motor unit motor neuron, its axon, and nerve terminals, and muscle
More informationDATE: 13 Mar 2015 CONTEXT AND POLICY ISSUES
TITLE: Immunomodulatory Drugs and Intravenous Immunoglobulin (IVIg) for Patients with Chronic Demyelinating Polyneuropathy Who Are in Remission: A Review of Clinical and Cost-effectiveness and Guidelines
More informationImmune Mediated Neuropathies
Immune Mediated Neuropathies Hernan Gatuslao, M.D. Assistant Professor Department of Neurology Virginia Commonwealth University School of Medicine AIDP and CIDP Acute inflammatory demyelinating polyneuropathy
More informationComparison of Plasmapheresis and Intravenous Immunoglobulin as Maintenance Therapies for Juvenile Myasthenia Gravis
Research Original Investigation Comparison of Plasmapheresis and Intravenous Immunoglobulin as Maintenance Therapies for Juvenile Myasthenia Gravis Wendy K. M. Liew, MBChB, MRCPCH; Christine A. Powell,
More informationNeuromuscular Junction Testing ELBA Y. GERENA MALDONADO, MD ACTING ASSISTANT PROFESSOR UNIVERSITY OF WASHINGTON MEDICAL CENTER
Neuromuscular Junction Testing ELBA Y. GERENA MALDONADO, MD ACTING ASSISTANT PROFESSOR UNIVERSITY OF WASHINGTON MEDICAL CENTER Objectives Neurophysiology Electrodiagnostic Evaluation Clinical Application
More informationJonathan Katz, MD CPMC
Jonathan Katz, MD CPMC Jonathan Katz, MD CPMC Jonathan Katz, MD CPMC Jonathan Katz, MD CPMC First, a bit of background Classic CIDP--TREATABLE MADSAM/Asymmetric Neuropathy Chronic Length Dependent Neuropathy-
More informationPatogenesi e terapia della Neuropatia Motoria Multifocale
26 Settembre 2014 Patogenesi e terapia della Neuropatia Motoria Multifocale Francesca Gallia Neurologia 2, Ist. Clin. Humanitas Rozzano, Milano Multifocal Motor Neuropathy Rare disorder characterized by:
More informationMYASTHENIA GRAVIS. Mr. D.Raju, M.pharm, Lecturer
MYASTHENIA GRAVIS Mr. D.Raju, M.pharm, Lecturer OUTLINE Background Anatomy Pathophysiology Clinical Presentation Treatment BACKGROUND Acquired autoimmune disorder Clinically characterized by: Weakness
More informationClinical Commissioning Policy Proposition:
Clinical Commissioning Policy Proposition: Rituximab for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), vasculitis of the peripheral nervous system
More informationMyasthenia Gravis. Stephen L. McKernan, DO. brief report INTRODUCTION DIAGNOSIS KEYWORDS:
38 Osteopathic Family Physician Volume 11, No. 1 January/February, 2019 Osteopathic Family Physician (2019) 38-42 brief report Stephen L. McKernan, DO Sam Houston State University Proposed College of Osteopathic
More informationHuman Physiology Lab (Biol 236L) Fall, 2015
1 Human Physiology Lab (Biol 236L) Fall, 2015 Name: Nursing Case Study: Muscle Weakness Chief Complaint: A 26-year-old woman with muscle weakness in the face. Patient Presentation: A 26-year-old woman
More informationThe role of plasmapheresis in Myasthenia Gravis. Ri 陳文科
The role of plasmapheresis in Myasthenia Gravis Ri 陳文科 Myaasthenia Gravis S/S: 2/3 initial symptoms: Ocular motor disturbances, ptosis or diplopia. 1/6:Oropharyngeal muscle weakness 1/10: limb weakness
More informationCritical Illness Polyneuropathy CIP and Critical Illness Myopathy CIM. Andrzej Sladkowski
Critical Illness Polyneuropathy CIP and Critical Illness Myopathy CIM Andrzej Sladkowski Potential causes of weakness in the ICU-1 Muscle disease Critical illness myopathy Inflammatory myopathy Hypokalemic
More informationAryendu Kumar Saini et al. Int. Res. J. Pharm. 2017, 8 (3) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article A REVIEW ON MYASTHENIA GRAVIS Aryendu Kumar Saini 1 *, Aditya Gupta 2, Shubham Singh 3, Hemendra Pati Tripathi
More informationMyasthenia Gravis and Lambert-Eaton Myasthenic Syndrome Michael W. Nicolle, MD
Review Article Downloaded from https://journals.lww.com/continuum by maxwo3znzwrcfjddvmduzvysskax4mzb8eymgwvspgpjoz9l+mqfwgfuplwvy+jmyqlpqmifewtrhxj7jpeo+505hdqh14pdzv4lwky42mcrzqckilw0d1o4yvrwmuvvhuyo4rrbviuuwr5dqytbtk/icsrdbt0hfryk7+zagvaltkgnudxdohhaxffu/7kno26hifzu/+bcy16w7w1bdw==
More informationPRIMARY DISEASES OF MYELIN. By: Shifaa Al Qa qa
PRIMARY DISEASES OF MYELIN By: Shifaa Al Qa qa Most diseases of myelin are primarily white matter disorders??? Myelinated axons most diseases of CNS myelin do not involve the peripheral nerves to any significant
More informationPeripheral Neurology: GBS and MG
Peripheral Neurology: GBS and MG Ashok Verma, M.D., DM Professor of Neurology Director, Kessenich Family MDA ALS Center and MDA Clinics University of Miami Miller School of Medicine Guillain-Barre Syndrome
More informationThe Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes An Observational Study
The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes An Observational Study Samantha K. Dunnigan 1, Hamid Ebadi 1, Ari Breiner 1, Hans D. Katzberg
More informationMyasthenia gravis. THE PET HEALTH LIBRARY By Wendy C. Brooks, DVM, DipABVP Educational Director, VeterinaryPartner.com
THE PET HEALTH LIBRARY By Wendy C. Brooks, DVM, DipABVP Educational Director, VeterinaryPartner.com Myasthenia gravis What You Need to Know to Understand this Disease Myasthenia gravis is a disease that
More informationEnvironmental Factors of Importance in Myasthenia Gravis
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1439 Environmental Factors of Importance in Myasthenia Gravis Emphasis on Physical Activity ELISABET WESTERBERG ACTA
More informationAuthors' objectives To evaluate the efficacy of intravenous immunoglobulin (IVIG) for neurologic conditions.
Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review Fergusson D, Hutton B, Sharma M, Tinmouth A, Wilson K, Cameron D W, Hebert P C CRD summary This review assessed
More informationIntravenous immunoglobulin (IVIG) in the treatment of chronic demyelinating polyradiculoneuropathy
Acta neurol. belg., 2001, 101, 147-151 Editorial Intravenous immunoglobulin (IVIG) in the treatment of chronic demyelinating polyradiculoneuropathy P. Y. K. VAN DEN BERGH Service de Neurologie, Centre
More informationMyasthenia gravis. What You Need to Know to Understand this Disease
Myasthenia gravis What You Need to Know to Understand this Disease Myasthenia gravis is a disease that interrupts the way nerves communicate with muscles. In order to understand this disease, you must
More informationReview Article Myasthenia Gravis: A Review of Available Treatment Approaches
SAGE-Hindawi Access to Research Autoimmune Diseases Volume 2011, Article ID 847393, 6 pages doi:10.4061/2011/847393 Review Article Myasthenia Gravis: A Review of Available Treatment Approaches Nils Erik
More informationNeuroimmunology. Innervation of lymphoid organs. Neurotransmitters. Neuroendocrine hormones. Cytokines. Autoimmunity
Neuroimmunology Innervation of lymphoid organs Neurotransmitters Neuroendocrine hormones Cytokines Autoimmunity CNS has two ways of contacting and regulating structures in the periphery Autonomic
More informationIntroduction and aims of the study
Introduction and aims of the study 1 Chapter 1 Motor neuron diseases include the most incapacitating and life-threatening illnesses but also rather benign disorders with only mild symptoms and slow progression.
More informationPage 1 of 6 Title Authored By Course No Contact Hour 1 An Overview of Myasthenia Gravis Ray Lengel RN, FNP, MS MG2061208 Purpose The goal of this course is to provide an understanding about myasthenia
More informationClinical predictors of steroid-induced exacerbation in myasthenia gravis
Journal of Clinical Neuroscience 13 (2006) 1006 1010 Clinical study Clinical predictors of steroid-induced exacerbation in myasthenia gravis Jong Seok Bae a, Seok Min Go a, Byoung Joon Kim b, * a Department
More informationNIH Public Access Author Manuscript J Clin Apher. Author manuscript; available in PMC 2014 February 01.
NIH Public Access Author Manuscript Published in final edited form as: J Clin Apher. 2013 February ; 28(1): 16 19. doi:10.1002/jca.21266. Therapeutic Plasma Exchange in Neurology: 2012 Irene Cortese, MD
More informationAn autoimmune perspective on neuromuscular diseases
An autoimmune perspective on neuromuscular diseases Colin Chalk MD,CM FRCPC Montreal General Hospital McGill University Schlomchik 2001 The proportion of neuromuscular patients who have an autoimmune cause
More informationAcute respiratory failure in the setting of Chronic In lammatory Demyelinating Polyneuropathy
Open Journal of Clinical & Medical Case Reports Volume 3 (2017) Issue 20 ISSN 2379-1039 Acute respiratory failure in the setting of Chronic In lammatory Demyelinating Polyneuropathy Joseph Burns*; Michael
More informationSurgery for the treatment of myasthenia gravis. Tim Batchelor Department of Thoracic Surgery Bristol Royal Infirmary
Surgery for the treatment of myasthenia gravis Tim Batchelor Department of Thoracic Surgery Bristol Royal Infirmary The role of thymectomy It is of considerable interest to find a relationship between
More informationCURRENT MEDICINE MYASTHENIA GRAVIS
MYASTHENIA GRAVIS M.E. Farrugia, Specialist Registrar in Neurology, and R.J. Swingler, Consultant Neurologist, Department of Neurology, Ninewells Hospital and Medical School, Dundee SUMMARY Myasthenia
More informationNHS England Reference: /P
Clinical Commissioning Policy: Rituximab for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocus motor neuropathy (MMN), vasculitis of the peripheral nervous system & IgM paraprotein-associated
More informationUPDATE IN NEUROMUSCULAR DISORDERS. Justin Kwan, MD University of Maryland Baltimore, MD
UPDATE IN NEUROMUSCULAR DISORDERS Justin Kwan, MD University of Maryland Baltimore, MD Peripheral nerve disorders Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic and disabling
More informationCorticosteroids in chronic inflammatory demyelinating polyneuropathy
https://doi.org/10.1007/s00415-018-8948-y ORIGINAL COMMUNICATION Corticosteroids in chronic inflammatory demyelinating polyneuropathy A retrospective, multicentre study, comparing efficacy and safety of
More informationDiabetes Care 36: , 2013
Pathophysiology/Complications O R I G I N A L A R T I C L E Conduction Slowing in Diabetic Sensorimotor Polyneuropathy SAMANTHA K. DUNNIGAN, MSC 1 HAMID EBADI, MD 1 ARI BREINER, MD 1 HANS D. KATZBERG,
More informationNIH Public Access Author Manuscript Lancet Neurol. Author manuscript; available in PMC 2009 August 24.
NIH Public Access Author Manuscript Published in final edited form as: Lancet Neurol. 2009 May ; 8(5): 475 490. doi:10.1016/s1474-4422(09)70063-8. Autoimmune myasthenia gravis: emerging clinical and biological
More informationSymptomatic pain treatments (carbamazepine and gabapentin) were tried and had only a transient and incomplete effect on the severe pain syndrome.
Laurencin 1 Appendix e-1 Supplementary Material: Clinical observations Patient 1 (48-year-old man) This patient, who was without a notable medical history, presented with thoracic pain and cough, which
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationORIGINAL CONTRIBUTION. Efficacy of Intravenous Immunoglobulin in Patients With IgG Monoclonal Gammopathy and Polyneuropathy
ORIGINAL CONTRIBUTION Efficacy of Intravenous Immunoglobulin in Patients With IgG Monoclonal Gammopathy and Polyneuropathy Kenneth C. Gorson, MD; Allan H. Ropper, MD; David H. Weinberg, MD; Robert Weinstein,
More informationCSCN Hot Topics What s New in the Treatment of Myasthenia Gravis? Dr. Fraser Moore CNSF Congress Victoria, BC Tuesday June 20 th 2017
Introduction CSCN Hot Topics What s New in the Treatment of Myasthenia Gravis? Dr. Fraser Moore CNSF Congress Victoria, BC Tuesday June 20 th 2017 The overall goal of this session is to look at recent
More information5.1 Alex.
5.1 Alex http://tinyurl.com/neuromakessense Alex is a 20-year-old full-time national serviceman. His only past medical history is asthma, presents to A&E with a 4-day history of bilateral finger weakness
More informationClinical & Experimental. Neuroimmunology. Japanese clinical guidelines for myasthenia gravis: Putting into practice
REVIEW ARTICLE Japanese clinical guidelines for myasthenia gravis: Putting into practice Hiroyuki Murai Clinical & Experimental Neuroimmunology Clinical and Experimental Neuroimmunology 6 (2015) 21 31
More informationFacts about Myasthenia Gravis
The information in this fact sheet was adapted by the MDNSW (06/06) from the MDA USA fact sheet (updated 11/05) with their kind permission. Facts about Myasthenia Gravis Myasthenia Gravis (MG), Lambert-Eaton
More informationPLASMA EXCHANGE J MANION NEPEAN HOSPITAL
PLASMA EXCHANGE J MANION NEPEAN HOSPITAL PLASMA The fluid portion of blood Normally approx 5% body weight or 3.5L in 70kg male Clots on standing unless anticoagulated Common plasma proteins are albumin,
More informationJCN Open Access INTRODUCTION ORIGINAL ARTICLE. 482 Copyright 2016 Korean Neurological Association
JCN Open Access pissn 1738-6586 / eissn 2005-5013 / J Clin Neurol 2016;12(4):482-488 / http://dx.doi.org/10.3988/jcn.2016.12.4.482 ORIGINAL ARTICLE Clinical Significance of Repetitive Compound Muscle Action
More informationCase Report An Unusual Case of Recurrent Guillain-Barre Syndrome of a Different Subtype Five Years after Initial Diagnosis
Case Reports in Neurological Medicine Volume 2013, Article ID 356157, 4 pages http://dx.doi.org/10.1155/2013/356157 Case Report An Unusual Case of Recurrent Guillain-Barre Syndrome of a Different Subtype
More information10/25/2018. Autoimmunity and how to treat it. Disclosure. Why do we get autoimmunity? James Verbsky MD/PhD Pediatric Rheumatology/Immunology
Autoimmunity and how to treat it James Verbsky MD/PhD Pediatric Rheumatology/Immunology Disclosure None I will mention drug names and some brand names but I have no financial interest or any other ties
More informationGuide to the use of nerve conduction studies (NCS) & electromyography (EMG) for non-neurologists
Guide to the use of nerve conduction studies (NCS) & electromyography (EMG) for non-neurologists What is NCS/EMG? NCS examines the conduction properties of sensory and motor peripheral nerves. For both
More informationIntravenous immunoglobulin response treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy
Predicting IVIg response in CIDP 1 http://hdl.handle.net/1765/105969 Intravenous immunoglobulin response in Chapter treatment-naïve 3.3 chronic inflammatory demyelinating polyradiculoneuropathy Intravenous
More informationA Case of Acute Sensory Neuropathy Associated with Contrast Enhancement of the Cauda Equina on Magnetic Resonance Imaging
61 Case Report St. Marianna Med. J. Vol. 33, pp. 61 66, 2005 A Case of Acute Sensory Neuropathy Associated with Contrast Enhancement of the Cauda Equina on Magnetic Resonance Imaging Toshinari Kobayashi
More informationThe Lambert-Eaton Myasthenic Syndrome an Overview
Review The Lambert-Eaton Myasthenic Syndrome an Overview Authors Siegfried Kohler, Andreas Meisel Affiliation Integrated Myasthenia Center, Department of Neurology, NeuroCure Clinical Research Center,
More informationClinical Study Headache Associated with Myasthenia Gravis: The Impact of Mild Ocular Symptoms
SAGE-Hindawi Access to Research Autoimmune Diseases Volume 2011, Article ID 840364, 4 pages doi:10.4061/2011/840364 Clinical Study Headache Associated with Myasthenia Gravis: The Impact of Mild Ocular
More informationC hronic inflammatory demyelinating polyneuropathy
PAPER Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin M Odaka, M Tatsumoto, K Susuki, K Hirata, N Yuki... See end of article for authors affiliations...
More informationInfection-Associated Neurological Syndromes
Infection-Associated Neurological Syndromes Anand P, MD PhD Medical Director, BloodCenter of Wisconsin Assistant Professor, Medical College of Wisconsin ASFA Annual Meeting San Antonio, TX, May 8th, 2015
More informationM yasthenia gravis is a potentially serious
690 REVIEW Update on myasthenia gravis B R Thanvi, T C N Lo... Myasthenia gravis is an autoimmune disorder caused by autoantibodies against the nicotinic acetylcholine receptor on the postsynaptic membrane
More informationEuropean Neurological Review Highlights
The Application of Clinical, Electrophysiological and Nerve Ultrasound Parameters in Distinguishing Acute-onset Chronic from Acute Inflammatory Demyelinating Polyneuropathy Antonios Kerasnoudis, Kallia
More informationJMSCR Vol 05 Issue 04 Page April 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i4.65 Clinical-Immunological Profile of Myasthenia
More informationDiagnosis and management of myasthenia gravis
Diagnosis and management of myasthenia gravis Sivakumar Sathasivam MRCP (UK), LLM, PhD Myasthenia gravis is the most common primary disorder of neuromuscular transmission and one of the most treatable
More informationIVIG (intravenous immunoglobulin) Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following documented indications: 1. Primary Immunodeficiency Disease (PID) with ONE of the a. Hypogammaglobulinemia,
More informationCoexistence of Amyotrophic Lateral Sclerosis and Myasthenia Gravis
Journal of Neuromuscular Diseases 1 (2014) 111 115 DOI 10.3233/JND-140007 IOS Press Case Report 111 Coexistence of Amyotrophic Lateral Sclerosis and Myasthenia Gravis Satoshi Yamashita a,, Akiko Fujimoto
More informationMyasthenia Gravis. Abstract. Overview. Daniel B. Drachman, MD 1
419 Daniel B. Drachman, MD 1 1 Department of Neurology & Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland Semin Neurol 2016;36:419 424. Address for correspondence Daniel B. Drachman,
More informationCIDP + MMN - how to diagnose and treat. Dr Hadi Manji
CIDP + MMN - how to diagnose and treat Dr Hadi Manji Outline Introduction CIDP Diagnosis Clinical features MRI Nerve conduction tests Lumbar puncture Nerve biopsy Treatment IV Ig Steroids Plasma Exchnage
More informationStudy population The study population comprised adult patients fulfilling the following inclusion criteria:
Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy McCrone P, Chisholm D, Knapp M, Hughes R, Comi G, Dalakas M C, Illa I,
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Soliris GENERIC NAME Eculizumab MANUFACTURER Alexion Pharmaceuticals, Inc. DATE OF APPROVAL October 23, 2017 PRODUCT LAUNCH DATE Currently commercially available REVIEW TYPE Review type 1 (RT1):
More informationCONCENTRIC NEEDLE JITTER ON STIMULATED FRONTALIS AND EXTENSOR DIGITORUM IN 20 MYASTHENIA GRAVIS PATIENTS
CONCENTRIC NEEDLE JITTER ON STIMULATED FRONTALIS AND EXTENSOR DIGITORUM IN 20 MYASTHENIA GRAVIS PATIENTS JOÃO ARIS KOUYOUMDJIAN, MD, PhD, 1 ADRIANA CRISTINA DA SILVA FANANI, MD, 1 and ERIK V. STÅLBERG,
More informationPharmacoeconomics of Intravenous Immunoglobulin in various Neurological Disorders
303 Pharmacoeconomics of Intravenous Immunoglobulin in various Neurological Disorders Ching-Piao Tsai Acta Neurol Taiwan 2010;19:304-309 INTRODUCTION Intravenous immunoglobulin (IVIG) has multiple actions
More informationImmunopathology of Guillain- Barré syndrome. L. Magy Service de Neurologie Centre de Référence 'Neuropathies Périphériques Rares' CHU Limoges, France
Immunopathology of Guillain- Barré syndrome L. Magy Service de Neurologie Centre de Référence 'Neuropathies Périphériques Rares' CHU Limoges, France What is Guillain-Barré syndrome? An immune-mediated
More information4/16/2018. Demystifying weakness: how to approach refractory myositis. Objectives. Disclosures. Off-label uses for medications will be discussed
Demystifying weakness: how to approach refractory myositis Jemima Albayda, MD Assistant Professor Johns Hopkins Myositis center Disclosures Off-label uses for medications will be discussed Objectives To
More informationDiseases of Muscle and Neuromuscular Junction
Diseases of Muscle and Neuromuscular Junction Diseases of Muscle and Neuromuscular Junction Neuromuscular Junction Muscle Myastenia Gravis Eaton-Lambert Syndrome Toxic Infllammatory Denervation Atrophy
More informationME Farrugia Consultant Neurologist, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
CME doi:10.4997/jrcpe.2011.111 2011 Royal College of Physicians of Edinburgh Myasthenic syndromes Consultant Neurologist, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK ABSTRACT
More informationDeterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern
Eftimov et al. BMC Neurology 2014, 14:72 RESEARCH ARTICLE Open Access Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern Filip Eftimov *, Marinus H Liesdek,
More informationPatient: RG DOB: NKDA
Patient: RG DOB: 09.26.1959 NKDA RG presented to the ED complaining of new onset generalized weakness Difficulty walking, fatigued with exertion, feeling off balance, dry mouth, and dysphasia HPI: approximately
More informationChronic Inflammatory Demyelinating Polyneuropathy (C.I.D.P.)
University Teaching Trust Chronic Inflammatory Demyelinating Polyneuropathy (C.I.D.P.) Neurology 0161 206 2323 All Rights Reserved 2016. Document for issue as handout. Information about Chronic Inflammatory
More informationIndex. Note: Page numbers of article titles are in boldface type.
Neurol Clin N Am 20 (2002) 605 617 Index Note: Page numbers of article titles are in boldface type. A ALS. See Amyotrophic lateral sclerosis (ALS) Amyotrophic lateral sclerosis (ALS) active denervation
More informationAUTOIMMUNE DISORDERS IN THE ACUTE SETTING
AUTOIMMUNE DISORDERS IN THE ACUTE SETTING Diagnosis and Treatment Goals Aimee Borazanci, MD BNI Neuroimmunology Objectives Give an update on the causes for admission, clinical features, and outcomes of
More informationClinical predictors for the prognosis of myasthenia gravis
Wang et al. BMC Neurology (2017) 17:77 DOI 10.1186/s12883-017-0857-7 RESEARCH ARTICLE Open Access Clinical predictors for the prognosis of myasthenia gravis Lili Wang *, Yun Zhang and Maolin He Abstract
More informationORIGINAL CONTRIBUTION. Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin
ORIGINAL CONTRIBUTION Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin A Randomized Double-blind Clinical Trial Philippe Gajdos, MD; Christine Tranchant, MD; Bernard Clair, MD;
More informationANAESTHESIA AND MYASTHENIA GRAVIS ANAESTHESIA TUTORIAL OF THE WEEK TH DECEMBER 2008
ANAESTHESIA AND MYASTHENIA GRAVIS ANAESTHESIA TUTORIAL OF THE WEEK 122 15 TH DECEMBER 2008 Dr Arnab Banerjee Hospital Luton & Dunstable Hospital NHS Trust Correspondence to abanerjeeuk@doctors.org.uk INTRODUCTION
More informationMotor and sensory nerve conduction studies
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Hands-on Course 2 Assessment of peripheral nerves function and structure in suspected peripheral neuropathies
More information